Literature DB >> 16893895

Human macrophage migration inhibitory factor: a proven immunomodulatory cytokine?

Alex Kudrin1, Martin Scott, Steven Martin, Chun-Wa Chung, Rachelle Donn, Andrew McMaster, Stuart Ellison, David Ray, Keith Ray, Michael Binks.   

Abstract

Macrophage migration inhibitory factor (MIF) is a pro-inflammatory mediator with the ability to induce various immunomodulatory responses and override glucocorticoid-driven immunosuppression. Some of these functions have been linked to the unusual enzymatic properties of the protein, namely tautomerase and oxidoreductase activities. However, there are conflicting reports regarding the functional role of these enzymatic properties in normal physiological homeostasis and disease progression. Therefore, we have produced a highly pure, virtually endotoxin-free recombinant MIF preparation and fully characterized this using a variety of biochemical and biophysical approaches. The recombinant protein, with demonstrable enzymatic activity, was then used to systematically examine the biological activity of MIF. Surprisingly, treatment with MIF alone failed to induce cytokine expression, with the exception of IL-8. However, co-treatment of lipopolysaccharide (LPS) in conjunction with MIF produced synergistic secretion of tumor necrosis factor-alpha, interleukin (IL)-1, and IL-8 compared with LPS alone. The potentiating effect of MIF was seen at physiologically relevant concentrations. These data suggest that MIF has no conventional cytokine activity but, rather, acts to modulate and amplify the response to LPS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16893895     DOI: 10.1074/jbc.M601103200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Novel half-life extended anti-MIF nanobodies protect against endotoxic shock.

Authors:  Amanda Sparkes; Patrick De Baetselier; Lea Brys; Inês Cabrito; Yann G-J Sterckx; Steve Schoonooghe; Serge Muyldermans; Geert Raes; Richard Bucala; Peter Vanlandschoot; Jo A Van Ginderachter; Benoît Stijlemans
Journal:  FASEB J       Date:  2018-01-25       Impact factor: 5.191

2.  Thiazolidinediones are partial agonists for the glucocorticoid receptor.

Authors:  L Matthews; A Berry; M Tersigni; F D'Acquisto; A Ianaro; D Ray
Journal:  Endocrinology       Date:  2008-09-18       Impact factor: 4.736

3.  Expression and regulation of macrophage migration inhibitory factor (MIF) in feeding American dog ticks, Dermacentor variabilis.

Authors:  Nalinda B Wasala; C J Bowen; Deborah C Jaworski
Journal:  Exp Appl Acarol       Date:  2012-04-05       Impact factor: 2.132

4.  A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance.

Authors:  Arthur A Vandenbark; Roberto Meza-Romero; Gil Benedek; Shayne Andrew; Jianya Huan; Yuan K Chou; Abigail C Buenafe; Rony Dahan; Yoram Reiter; Jeffery L Mooney; Halina Offner; Gregory G Burrows
Journal:  J Autoimmun       Date:  2012-09-29       Impact factor: 7.094

5.  Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with Steroid-sparing Potential.

Authors:  Joshua Bloom; Christine Metz; Saisha Nalawade; Julian Casabar; Kai Fan Cheng; Mingzhu He; Barbara Sherry; Thomas Coleman; Thomas Forsthuber; Yousef Al-Abed
Journal:  J Biol Chem       Date:  2016-10-28       Impact factor: 5.157

6.  Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor.

Authors:  Vinay Trivedi-Parmar; William L Jorgensen
Journal:  J Med Chem       Date:  2018-06-04       Impact factor: 7.446

7.  Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984-2002.

Authors:  C Herder; N Klopp; J Baumert; M Müller; N Khuseyinova; C Meisinger; S Martin; T Illig; W Koenig; B Thorand
Journal:  Diabetologia       Date:  2007-08-22       Impact factor: 10.122

8.  The macrophage migration inhibitory factor homolog of Entamoeba histolytica binds to and immunomodulates host macrophages.

Authors:  Shannon N Moonah; Mayuresh M Abhyankar; Rashidul Haque; William A Petri
Journal:  Infect Immun       Date:  2014-05-12       Impact factor: 3.441

9.  Structures of Leishmania major orthologues of macrophage migration inhibitory factor.

Authors:  Julia M Richardson; Lesley S Morrison; Nicholas D Bland; Sandra Bruce; Graham H Coombs; Jeremy C Mottram; Malcolm D Walkinshaw
Journal:  Biochem Biophys Res Commun       Date:  2009-01-31       Impact factor: 3.575

10.  Differential and cell-type specific regulation of responses to Toll-like receptor agonists by ISO-1.

Authors:  Peter W West; Lisa C Parker; Jon R Ward; Ian Sabroe
Journal:  Immunology       Date:  2008-03-18       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.